PriceTargets.com logo

Ascentage Pharma Group International - AAPG Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $46.67
  • Forecasted Upside: 99.94%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 2 Strong Buy Ratings
$23.34 As of 05/1/2026 04:59 PM ET
▲ +0.46 (2.01%)

This chart shows the closing price for AAPG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ascentage Pharma Group International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AAPG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AAPG

Analyst Price Target is $46.67
▲ +99.94% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Ascentage Pharma Group International in the last 3 months. The average price target is $46.67, with a high forecast of $51.00 and a low forecast of $40.00. The average price target represents a 99.94% upside from the last price of $23.34.

This chart shows the closing price for AAPG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Ascentage Pharma Group International.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2026
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/3/2026
  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2026

Latest Recommendations

  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/24/2026Deutsche Bank AktiengesellschaftInitiated CoverageBuy$40.00
4/13/2026BTIG ResearchReiterated RatingBuy ➝ Buy$48.00
4/6/2026China Intl CapUpgradeStrong-Buy
3/26/2026BTIG ResearchReiterated RatingBuy ➝ Buy$48.00
3/12/2026BTIG ResearchInitiated CoverageBuy$48.00
3/11/2026BTIG ResearchUpgradeStrong-Buy
1/13/2026Rodman & RenshawInitiated CoverageBuy$48.00
12/15/2025Lucid Cap MktsUpgradeStrong-Buy
12/4/2025OppenheimerInitiated CoverageOutperform$45.00
11/24/2025Truist FinancialSet Target$51.00
11/24/2025Truist FinancialInitiated CoverageBuy$51.00
11/10/2025BTIG ResearchInitiated CoverageBuy$50.00
11/5/2025Piper SandlerInitiated CoverageOverweight$48.00
3/27/2025JPMorgan Chase & Co.Initiated CoverageOverweight
(Data available from 5/3/2021 forward)

News Sentiment Rating

0.72 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 0 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
2/2/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2026
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026

Current Sentiment

  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Ascentage Pharma Group International logo
Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Read More

Today's Range

Now: $23.34
Low: $22.66
High: $23.34

50 Day Range

MA: $24.32
Low: $19.11
High: $27.69

52 Week Range

Now: $23.34
Low: $19.11
High: $48.45

Volume

914 shs

Average Volume

2,691 shs

Market Capitalization

$2.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Ascentage Pharma Group International?

The following equities research analysts have issued reports on Ascentage Pharma Group International in the last year: BTIG Research, China Intl Cap, Deutsche Bank Aktiengesellschaft, Lucid Cap Mkts, Oppenheimer Holdings, Inc., Piper Sandler, Rodman & Renshaw, and Truist Financial Corporation.
View the latest analyst ratings for AAPG.

What is the current price target for Ascentage Pharma Group International?

0 Wall Street analysts have set twelve-month price targets for Ascentage Pharma Group International in the last year. Their average twelve-month price target is $46.67, suggesting a possible upside of 99.9%. Truist Financial Corporation has the highest price target set, predicting AAPG will reach $51.00 in the next twelve months. Deutsche Bank Aktiengesellschaft has the lowest price target set, forecasting a price of $40.00 for Ascentage Pharma Group International in the next year.
View the latest price targets for AAPG.

What is the current consensus analyst rating for Ascentage Pharma Group International?

Ascentage Pharma Group International currently has 6 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AAPG will outperform the market and that investors should add to their positions of Ascentage Pharma Group International.
View the latest ratings for AAPG.

What other companies compete with Ascentage Pharma Group International?

Other companies that are similar to Ascentage Pharma Group International include Vaxcyte, Nuvalent, Cytokinetics, Krystal Biotech and Qiagen. Learn More about companies similar to Ascentage Pharma Group International.

How do I contact Ascentage Pharma Group International's investor relations team?

Ascentage Pharma Group International's physical mailing address is 68 XINQING ROAD, SUZHOU INDUSTRIAL PARK, SUZHOU , JIANGSU, China. The company's listed phone number is 86 512 8555 7777 and its investor relations email address is [email protected]. The official website for Ascentage Pharma Group International is www.ascentage.com. Learn More about contacing Ascentage Pharma Group International investor relations.